Lorenzo Nibid

Campus Bio Medico University Hospital
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (62)

Year:

2026

Background/Objectives: Thymomas are the most common tumors of the anterior mediastinum. While early-stage disease often has a favorable prognosis, therapeutic options in advanced stages remain limited. Moreover, the molecular profile of thymomas is still poorly characterized. In the present study, we explored the presence of targetable mutations and programmed death-ligand 1 (PD-L1) expression in a cohort of surgically resected thymomas. Furthermore, we investigated the correlation between PD-L1 expression, histological subtype, and risk of recurrence in patients who underwent curative-intent thymectomy. Methods: Mutational profiling was performed using a DNA-based NGS Cancer Panel of 16 genes. PD-L1 expression was evaluated via Tumor Proportion Score (TPS), and thymomas with TPS ≥ 50% were identified as high expressors. The associations with histological subtype and disease-free survival (DFS) were analyzed using logistic regression, Cox proportional hazards models, and Kaplan–Meier survival curves. Results: In our study, 2/37 (5.4%) of tested neoplasms (type AB and B2 thymoma) reported as a PIK3CA mutation; no other targetable mutations were observed. Moreover, high PD-L1 expression (≥50%) was reported in (15/37) 40.5% of patients and was significantly associated with aggressive histological subtypes (B2 and B3) (p < 0.001). Logistic regression analysis showed that high PD-L1 expression was a significant predictor of aggressive histology (McFadden’s R2 = 0.268, p < 0.001), with an odds ratio of 15.5 (95% CI: 2.9–83.4; p = 0.001). During follow-up, 5/37 (13.5%) of patients experienced disease recurrence; however, no significant difference in DFS was found between high and low PD-L1 expression groups. Conclusions: Our data confirm the presence of PIK3CA mutations in thymomas and encourage the exploration the potential role of molecular target therapy in this setting. Moreover, we underlined that high PD-L1 expression level is associated with more aggressive thymoma subtypes and may have a role as a prognostic biomarker. These findings support the need for further studies on the potential role of molecular and predictive pathology in thymic epithelial tumors.

Year:

2026

Year:

2026

Hodgkin lymphoma (HL) is a type of lymphoma, characterized by the presence of abnormal Reed‐Sternberg cells. It typically affects lymph nodes, generally in the upper body (such as neck, chest, and armpits). It can also involve the spleen, liver, and bone marrow. In the literature, there are sporadic cases of atypical localization of HL. The aim of this article is to report a peculiar case of HL in a 55‐year‐old male presenting with primary epitrochlear lymphadenopathy as the only localization of disease, also performing a literature review on this atypical presentation. We also summarized the possible underlying malignant pathologies that arise from the soft tissues of the upper limb adjacent to the elbow.

Year:

2025

Background: Approximately 25.0% of metastatic prostate cancer patients harbour DNA damage repair mutations, including BRCA1 and BRCA2, which are actionable targets for poly(ADP-ribose) polymerase (PARP) inhibitors. Accurate detection of BRCA1/2 mutations is critical for guiding targeted therapies, but crucial pre-analytical factors, such as tissue storage duration and DNA fragmentation, drastically affect the reliability of next-generation sequencing (NGS) using real-world diagnostic specimens. Methods: This multicentre study analysed 954 formalin-fixed paraffin-embedded tissue samples from 11 centres, including 559 biopsies and 395 surgical specimens. This study examined the impact of storage duration ( 2 years) and DNA parameters (concentration and fragmentation index) on NGS success rates. Logistic regression and Cox regression analyses were used to assess correlations between these factors and sequencing outcomes. Results: NGS success rates decreased significantly with longer storage, from 87.8% ( 2 years). Samples with higher DNA concentrations and fragmentation indexes had higher success rates (p < 0.001). Surgical specimens had superior success rates (83.3%) compared with biopsies (72.8%) due to better DNA quality. The DNA degradation rate was more pronounced in older samples, underscoring the negative impact of extended storage. Conclusions: Timely testing of BRCA1/2 mutations is critical for optimizing the identification of prostate cancer patients eligible for PARP inhibitors. Surgical specimens provide more reliable results than biopsies and minimizing the storage duration significantly enhances testing outcomes. Standardizing pre-analytical and laboratory procedures across centres is essential to ensure personalized treatments and improve patient outcomes.

Year:

2025

Importance Only a small fraction of patients with advanced non−small cell lung cancer (NSCLC) respond to immune checkpoint inhibitor (ICI) treatment. For optimal personalized NSCLC care, it is imperative to identify patients who are most likely to benefit from immunotherapy. Objective To develop a supervised deep learning−based ICI response prediction method; evaluate its performance alongside other known predictive biomarkers; and assess its association with clinical outcomes in patients with advanced NSCLC. Design, Setting, and Participants This multicenter cohort study developed and independently validated a deep learning−based response stratification model for predicting ICI treatment outcome in patients with advanced NSCLC from whole slide hematoxylin and eosin–stained images. Images for model development and validation were obtained from 1 participating center in the US and 3 in the European Union (EU) from August 2014 to December 2022. Data analyses were performed from September 2022 to May 2024. Exposure Monotherapy with ICIs. Main Outcomes and Measures Model performance measured by clinical end points and objective response rate (ORR) differentiation power vs other predictive biomarkers, ie, programmed death-ligand 1 (PD-L1), tumor mutational burden (TMB), and tumor-infiltrating lymphocytes (TILs). Results A total of 295 581 image tiles from 958 patients (mean [SD] age, 66.0 [10.6] years; 456 [48%] females and 502 [52%] males) treated with ICI for NSCLC were included in the analysis. The US-based development cohort consisted of 614 patients with median (IQR) follow-up time of 54.5 (38.2-68.1) months, and the EU-based validation cohort, 344 patients with 43.3 (27.4-53.9) months of follow-up. The ORR to ICI was 26% in the developmental cohort and 28% in the validation cohort. The deep learning model’s area under the receiver operating characteristic curve (AUC) for ORR was 0.75 (95% CI, 0.64-0.85) in the internal test set and 0.66 (95% CI, 0.60-0.72) in the validation cohort. In a multivariable analysis, the deep learning model’s score was an independent predictor of ICI response in the validation cohort for both progression-free (hazard ratio, 0.56; 95% CI, 0.42-0.76; P < .001) and overall survival (hazard ratio, 0.53; 95% CI, 0.39-0.73; P < .001). The tuned deep learning model achieved a higher AUC than TMB, TILs, and PD-L1 in the internal set; in the validation cohort, it was superior to TILs and comparable with PD-L1 (AUC, 0.67; 95% CI, 0.60-0.74), with a 10-percentage point improvement in specificity. In the validation cohort, combining the deep learning model with PD-L1 scores achieved an AUC of 0.70 (95% CI, 0.63-0.76), outperforming either marker alone, with a response rate of 51% compared to 41% for PD-L1 (≥50%) alone. Conclusions and Relevance The findings of this cohort study demonstrate a strong and independent deep learning−based feature associated with ICI response in patients with NSCLC across various cohorts. Clinical use of this deep learning model could refine treatment precision and better identify patients who are likely to benefit from ICI for treatment of advanced NSCLC.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (44)

Alessandro Di Federico

University of Bologna

ITALY
View details

Pasquale Pisapia

Assistant Professor of Anatomic Pathology

University of Naples Federico II

ITALY
View details

Umberto Malapelle

-

ITALY
View details

Bruno Beomonte Zobel

Head of the Department

Università Campus Bio-Medico

ITALY
View details

Giuseppe Tonini

Full Professor of Medical Oncology

Campus Bio Medico University Hospital

ITALY
View details

Marco Gaetano Tucci

Associate Professor

University of Bari

ITALY
View details

Matteo Tortora

Assistant Professor

University of Genova

ITALY
View details

Vincenzo L'Imperio

Assistant Professor

Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano-Bicocca

ITALY
View details

David J. Pinato

Imperial College London

UNITED KINGDOM
View details

Cristiana Bellan

MD, PhD, Associated professor

University of Siena

ITALY
View details

Bruno Vincenzi

Professor of Medical Oncology

Università Campus Bio-Medico

ITALY
View details

Alessandro Gambella

University of Pittsburgh

UNITED STATES
View details

Rosa Sicilia

Assistant Professor (RTDA)

Università Campus Bio-Medico di Roma

ITALY
View details

Stefano Marletta

University of Verona

ITALY
View details

Maria Grazia Vitale

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Sebastiano Buti

Ricercatore a contratto tipo B

University of Parma

ITALY
View details

Alessandro Caputo

-

ITALY
View details

maria rosaria raspollini

University of Florence

ITALY
View details

Marco Ferrari

Associate Professor

University of Padova

ITALY
View details

Luca Mastracci

Consultant - Assistant Professor

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro

ITALY
View details

Alessio Cortellini

Imperial College London

UNITED KINGDOM
View details

Andrea Vecchione

-

ITALY
View details

Michele Fiore

Università Campus Bio-Medico di Roma

ITALY
View details

Maria Giuseppa Vitale

-

ITALY
View details

Giuseppe Ingravallo

Prof

University of Bari Aldo Moro

ITALY
View details

Silvia Uccella

IRCCS Humanitas Research Hospital

ITALY
View details

Rosario Francesco Grasso

-

ITALY
View details

Paolo Marchetti

Sapienza University of Rome

ITALY
View details

Giuseppe Nicolò Fanelli

University of Pisa

ITALY
View details

Michele Ghidini

Docenti di ruolo di IIa fascia

University of Insubria

ITALY
View details

Francesco Pantano

National Academic Qualification as Full Professor (Abilitazione Scientifica Nazionale a Professore di I Fascia) in Hematology, Oncology and Rheumatology (MED 06/D3)

Ministero dell’Istruzione, dell’Università e della Ricerca

ITALY
View details

Alfonso Baldi

Professore Associato in Anatomia Patologica

Link Campus University

ITALY
View details

Dario de Biase

Associate professor equivalent to senior biologist

University of Bologna

ITALY
View details

Melissa Bersanelli

Adjunct Professor in Medical Oncology

University of Parma

ITALY
View details

Fabio Pagni

University of Milano-Bicocca

ITALY
View details

Giancarlo Troncone

-

ITALY
View details

olga nigro

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Alessandro Russo

Humanitas University

ITALY
View details

Albino Eccher

-

ITALY
View details

MICHELE DE TURSI

ASSOCIATE PROFESSOR

University "G. d'Annunzio"

ITALY
View details

Paolo Antonio Ascierto

Full Professor

Università degli Studi di Napoli Federico II

ITALY
View details

Giuseppe Perrone

Università Campus Bio-Medico di Roma

ITALY
View details

Antonio D'Alessio

King's College Hospital

UNITED KINGDOM
View details

Nicola Fusco

Director

University of Milan

ITALY
View details